Abstract
Spinal muscular atrophy (SMA) is caused by mutations that reduce the level of the survival motor neuron protein (SMN) resulting in death of alpha-motor neurons, yet it is unclear why these cells are preferentially affected by a reduction in this ubiquitously-expressed protein. In mouse models of SMA, one of the earliest events detected is defects at the neuromuscular junction (NMJ). Although NMJs are established at a normal frequency, there are structural as well as functional perturbations and a lack of maturation of the primitive synapse. These early defects are followed by loss of the NMJ, denervation of the muscle and onset of muscle atrophy. In this review, we discuss our current understanding of the contribution of NMJ dysfunction in SMA disease pathogenesis, and also provide an overview of therapies currently under preclinical and clinical development for treatment of SMA.
Keywords: Genetic disease, neuromuscular junction, pathogenesis, spinal muscular atrophy.
Current Molecular Medicine
Title:At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Volume: 13 Issue: 7
Author(s): B. B. Goulet, R. Kothary and R. J. Parks
Affiliation:
Keywords: Genetic disease, neuromuscular junction, pathogenesis, spinal muscular atrophy.
Abstract: Spinal muscular atrophy (SMA) is caused by mutations that reduce the level of the survival motor neuron protein (SMN) resulting in death of alpha-motor neurons, yet it is unclear why these cells are preferentially affected by a reduction in this ubiquitously-expressed protein. In mouse models of SMA, one of the earliest events detected is defects at the neuromuscular junction (NMJ). Although NMJs are established at a normal frequency, there are structural as well as functional perturbations and a lack of maturation of the primitive synapse. These early defects are followed by loss of the NMJ, denervation of the muscle and onset of muscle atrophy. In this review, we discuss our current understanding of the contribution of NMJ dysfunction in SMA disease pathogenesis, and also provide an overview of therapies currently under preclinical and clinical development for treatment of SMA.
Export Options
About this article
Cite this article as:
Goulet B. B., Kothary R. and Parks J. R., At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression, Current Molecular Medicine 2013; 13 (7) . https://dx.doi.org/10.2174/15665240113139990044
DOI https://dx.doi.org/10.2174/15665240113139990044 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Smoking and Congenital Heart Disease: The Epidemiological and Biological Link
Current Pharmaceutical Design Cardiovascular Risk in Postmenopausal Women with Polycystic Ovary Syndrome
Current Vascular Pharmacology Interaction of Anthocyanins with Drug-metabolizing and Antioxidant Enzymes
Current Medicinal Chemistry A Review on Noscapine, and its Impact on Heme Metabolism
Current Drug Metabolism Neuronal and Vascular Oxidative Stress in Alzheimers Disease
Current Neuropharmacology Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA Myocardial Revascularization for the Elderly: Current Options, Role of Off-pump Coronary Artery Bypass Grafting and Outcomes
Current Cardiology Reviews Meet Our Editorial Board Member
Current Stem Cell Research & Therapy The Role of Redox Dysregulation in the Inflammatory Response to Acute Myocardial Ischaemia-reperfusion Injury - Adding Fuel to the Fire
Current Medicinal Chemistry Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets NAD in Skin: Therapeutic Approaches for Niacin
Current Pharmaceutical Design Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Rationale and Design of the ACS-BP Study: Prognostic Value of In-Hospital Blood Pressure and Indices of Atherosclerosis in Acute Coronary Syndromes
Current Vascular Pharmacology Cardiac SPECT-CT and PET-CT Imaging
Current Medical Imaging Editorial [Hot Topic: Perspectives of New Antihypertensive Drugs (Executive Editor: Ji-Guang Wang)]
Current Pharmaceutical Design Sea, Carbohydrates and Clotting: A Triad on the Road of Drug Discovery
Mini-Reviews in Medicinal Chemistry Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Human Induced Pluripotent Stem Cells for Inherited Cardiovascular Diseases Modeling
Current Stem Cell Research & Therapy Mononuclear Cell Recruitment and Inflammation in Atherosclerosis
Vascular Disease Prevention (Discontinued) Meet Our Editorial Board Member
Current Drug Delivery